In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine

Current Opinion in Pharmacology

Volumn 9, Issue 5, 2009, Pages 669-676

  Vidalin, Olivier ^a   Muslmani, Machadiya ^a   Estienne, Clément ^a   Echchakir, Hamid ^a   Abina, Amine M ^a  

^a NOKAD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN II; CHEMOKINE RECEPTOR CCR5; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROPOIETIN; FREUND ADJUVANT; HUNTINGTIN; IMATINIB; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; KEYHOLE LIMPET HEMOCYANIN; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; OVALBUMIN; RANTES; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TETANUS TOXOID; THROMBOPOIETIN; TUBERCULIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VIRUS VECTOR;

ACCURACY; CAENORHABDITIS ELEGANS; CHRONIC MYELOID LEUKEMIA; DISEASE MODEL; DRUG TARGETING; EXPERIMENTAL MODEL; HUMAN; HUNTINGTON CHOREA; HYPERCHOLESTEROLEMIA; IMMUNIZATION; IN VIVO STUDY; KNOCKOUT MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; RNA INTERFERENCE; TECHNOLOGY; VALIDATION STUDY; VIRAL GENE DELIVERY SYSTEM; VIRUS LIKE AGENT;

ANIMALS; ANTIBODIES; BIOLOGICAL ASSAY; DRUG DISCOVERY; GENE EXPRESSION REGULATION; GENE KNOCKOUT TECHNIQUES; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, ANIMAL; PHENOTYPE; PROTEINS; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 70349431230     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.06.017     Document Type: Review

References (54)

1. Kaletta T., and Hengartner M.O. Finding function in novel targets: C. elegans as a model organism. Nat Rev Drug Discov 5 (2006) 387-398
2. Zon L.I., and Peterson R.T. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov 4 (2005) 35-44
3. Zan Y., Haag J.D., Chen K.S., Shepel L.A., Wigington D., Wang Y.R., Hu R., Lopez-Guajardo C.C., Brose H.L., Porter K.I., et al. Production of knockout rats using ENU mutagenesis and a yeast-based screening assay. Nat Biotechnol 21 (2003) 645-651
4. Ostertag E.M., Madison B.B., and Kano H. Mutagenesis in rodents using the L1 retrotransposon. Genome Biol 8 Suppl. 1 (2007) S16. This report shows that L1 retroposons can be modified to increase their activity and mutagenic power and describes a new powerful tool for performing random mutagenesis in rodents.
5. Li P., Tong C., Mehrian-Shai R., Jia L., Wu N., Yan Y., Maxson R.E., Schulze E.N., Song H., Hsieh C.L., et al. Germline competent embryonic stem cells derived from rat blastocysts. Cell 135 (2008) 1299-1310. Description of the first embryonic stem cells from rat blastocysts able to transmit the cell line genome to offspring. One of the first two reports describing authentic rat ES cells suitable for creating models for the study of human diseases.
6. Buehr M., Meek S., Blair K., Yang J., Ure J., Silva J., McLay R., Hall J., Ying Q.L., and Smith A. Capture of authentic embryonic stem cells from rat blastocysts. Cell 135 (2008) 1287-1298. The second independent study establishing rat ES cell line are suitable for transmitting a genome to offspring and opening the way for the development of new genetically modified rat models.
7. Zambrowicz B.P., and Sands A.T. Knockouts model the 100 best-selling drugs--will they model the next 100?. Nat Rev Drug Discov 2 (2003) 38-51
8. Munroe R.J., Bergstrom R.A., Zheng Q.Y., Libby B., Smith R., John S.W., Schimenti K.J., Browning V.L., and Schimenti J.C. Mouse mutants from chemically mutagenized embryonic stem cells. Nat Genet 24 (2000) 318-321
9. Nolan P.M., Peters J., Strivens M., Rogers D., Hagan J., Spurr N., Gray I.C., Vizor L., Brooker D., Whitehill E., et al. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet 25 (2000) 440-443
10. Beutler B.A. TLRs and innate immunity. Blood 113 (2009) 1399-1407. On the basis of the observation of changes in a simple phenotype (production of IFN by macrophages from mutated mice). Beutler and colleagues deciphered the pathway for mouse Toll-like receptors.
11. Keays D.A., Tian G., Poirier K., Huang G.J., Siebold C., Cleak J., Oliver P.L., Fray M., Harvey R.J., Molnar Z., et al. Mutations in alpha-tubulin cause abnormal neuronal migration in mice and lissencephaly in humans. Cell 128 (2007) 45-57
12. Scrable H. Say when: reversible control of gene expression in the mouse by lac. Semin Cell Dev Biol 13 (2002) 109-119
13. Lewandoski M. Conditional control of gene expression in the mouse. Nat Rev Genet 2 (2001) 743-755
14. Imai T., Jiang M., Chambon P., and Metzger D. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes. Proc Natl Acad Sci USA 98 (2001) 224-228
15. Loonstra A., Vooijs M., Beverloo H.B., Allak B.A., van Drunen E., Kanaar R., Berns A., and Jonkers J. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci USA 98 (2001) 9209-9214
16. Wu H., Liu X., Jaenisch R., and Lodish H.F. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83 (1995) 59-67
17. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., Kitamura Y., Matsushima K., Yoshida N., Nishikawa S., et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393 (1998) 591-594
18. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., and Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393 (1998) 595-599
19. Ferry G., Giganti A., Coge F., Bertaux F., Thiam K., and Boutin J.A. Functional invalidation of the autotaxin gene by a single amino acid mutation in mouse is lethal. FEBS Lett 581 (2007) 3572-3578
20. McCaffrey A.P., Meuse L., Pham T.T., Conklin D.S., Hannon G.J., and Kay M.A. RNA interference in adult mice. Nature 418 (2002) 38-39
21. Ameres S.L., Martinez J., and Schroeder R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130 (2007) 101-112
22. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J., Yamasaki S., Itaya M., Pan Y., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452 (2008) 591-597
23. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., Yoder J., Reeves P., Pandey R.K., Rajeev K.G., et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 104 (2007) 17204-17209
24. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., Harborth J., Heyes J.A., Jeffs L.B., John M., et al. RNAi-mediated gene silencing in non-human primates. Nature 441 (2006) 111-114. This report shows the clinical relevance of RNAi-mediated gene silencing; the silencing of apolipoprotein B in cynomolgus monkeys and opens the door to a new potential class of drugs.
25. Hogrefe R.I., Lebedev A.V., Zon G., Pirollo K.F., Rait A., Zhou Q., Yu W., and Chang E.H. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 25 (2006) 889-907
26. Peer D., Zhu P., Carman C.V., Lieberman J., and Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 104 (2007) 4095-4100
27. Kumar P., Ban H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., Laouar A., Yao J., Haridas V., Habiro K., et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134 (2008) 577-586
28. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., Lee S.K., Shankar P., and Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448 (2007) 39-43
29. Frank-Kamenetsky M., Grefhorst A., Anderson N.N., Racie T.S., Bramlage B., Akinc A., Butler D., Charisse K., Dorkin R., Fan Y., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105 (2008) 11915-11920
30. Naftzger C., Takechi Y., Kohda H., Hara I., Vijayasaradhi S., and Houghton A.N. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 93 (1996) 14809-14814. A demonstration that cross-reactive antibody responses can be achieved against an endogenous proteins without breaking tolerance by using an altered source of antigen. Cross-reactive antibody tumour protection against the tyrosinase-related protein 1 (gp75).
31. Abina M.A., Tulliez M., Duffour M.T., Debili N., Lacout C., Villeval J.L., Wendling F., Vainchenker W., and Haddada H. Thrombopoietin (TPO) knockout phenotype induced by cross-reactive antibodies against TPO following injection of mice with recombinant adenovirus encoding human TPO. J Immunol 160 (1998) 4481-4489. The First demonstration of a full protein functional knockout model of the thrombopoïetin protein in vivo after active immunisation in mice using adenoviral vectors. The model generated displays the same phenotype as the genetic knockout model for a period of at least eight months.
32. Zagury D., Burny A., and Gallo R.C. Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines. Proc Natl Acad Sci USA 98 (2001) 8024-8029
33. O'Rand M.G., Widgren E.E., Sivashanmugam P., Richardson R.T., Hall S.H., French F.S., VandeVoort C.A., Ramachandra S.G., Ramesh V., and Jagannadha Rao A. Reversible immunocontraception in male monkeys immunized with eppin. Science 306 (2004) 1189-1190. Successful model of protein functional knockout for immunocontraception in a non-human primate model. In this report, the total neutralisation induced by cross-reactivity between human recombinant protein and endogenous protein can persist for over a year and a half and is totally reversible.
34. Engelhorn M.E., Guevara-Patino J.A., Noffz G., Hooper A.T., Lou O., Gold J.S., Kappel B.J., and Houghton A.N. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 12 (2006) 198-206
35. Chackerian B., Briglio L., Albert P.S., Lowy D.R., and Schiller J.T. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 78 (2004) 4037-4047
36. Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., Volk H.D., Stocker H., Muller P., Jennings G.T., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371 (2008) 821-827. This is the first report of active immunisation in humans with demonstrated safety and efficacy in neutralisation of an endogenous target. The chosen model was the neutralisation of human angiotensin II protein for controlling hypertension using a recombinant virus-like particle vaccine.
37. de Sauvage F.J., Carver-Moore K., Luoh S.M., Ryan A., Dowd M., Eaton D.L., and Moore M.W. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 183 (1996) 651-656
38. Gurney A.L., Carver-Moore K., de Sauvage F.J., and Moore M.W. Thrombocytopenia in c-mpl-deficient mice. Science 265 (1994) 1445-1447
39. Hu Y., Swerdlow S., Duffy T.M., Weinmann R., Lee F.Y., and Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 103 (2006) 16870-16875
40. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
41. Wernig G., Kharas M.G., Okabe R., Moore S.A., Leeman D.S., Cullen D.E., Gozo M., McDowell E.P., Levine R.L., Doukas J., et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13 (2008) 311-320
42. Geron I., Abrahamsson A.E., Barroga C.F., Kavalerchik E., Gotlib J., Hood J.D., Durocher J., Mak C.C., Noronha G., Soll R.M., et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell 13 (2008) 321-330
43. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806
44. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
45. Lee J.S., Chu I.S., Mikaelyan A., Calvisi D.F., Heo J., Reddy J.K., and Thorgeirsson S.S. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36 (2004) 1306-1311
46. Zender L., Xue W., Zuber J., Semighini C.P., Krasnitz A., Ma B., Zender P., Kubicka S., Luk J.M., Schirmacher P., et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135 (2008) 852-864
47. Vousden K.H., and Prives C. Blinded by the light: the growing complexity of p53. Cell 137 (2009) 413-431
48. Dragunow M. The adult human brain in preclinical drug development. Nat Rev Drug Discov 7 (2008) 659-666
49. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discov 8 (2009) 23-33
50. Fernandez M.L., and Volek J.S. Guinea pigs: a suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation. Nutr Metab (Lond) 3 (2006) 17. The pertinence of the animal model used to study human situation is crucial. This report shows that despite the fact that transgenic animals or genetic knockout animals have been much used to study cholesterol metabolism, these models differ from human conditions. The guinea pig is a far more suitable model that can potentially be assessed for target validations using either siRNA or protein knockout.
51. Aitman T.J., Critser J.K., Cuppen E., Dominiczak A., Fernandez-Suarez X.M., Flint J., Gauguier D., Geurts A.M., Gould M., Harris P.C., et al. Progress and prospects in rat genetics: a community view. Nat Genet 40 (2008) 516-522
52. Donsante A., Miller D.G., Li Y., Vogler C., Brunt E.M., Russell D.W., and Sands M.S. AAV vector integration sites in mouse hepatocellular carcinoma. Science 317 (2007) 477
53. McLaurin J., Cecal R., Kierstead M.E., Tian X., Phinney A.L., Manea M., French J.E., Lambermon M.H., Darabie A.A., Brown M.E., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8 (2002) 1263-1269
54. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 (2003) 448-452